Biopharmaceutical Manufacturing: An Evolving Industry

by David Gemmell | August 22, 2022

Chemical Engineering Magazine has published its second article of the biopharmaceutical manufacturing series, written by Biomanufacturing Engineer, David Gemmell. In the article he explores how chemical engineers play their part in the manufacture of biopharma products from traditional vaccines to new modalities such as mRNA-based therapeutics.

Learn more about modern manufacturing philosophies in the second article of the series, Biopharmaceutical Manufacturing: An Evolving Industry.

David Gemmell

David Gemmell has been working for

Merck KGaA, Darmstadt, Germany

MilliporeSigma

for over six years. David is currently employed with the Technical & Scientific Solutions MSAT (Manufacturing Sciences & Technology) department. David’s primary focus is on optimising or troubleshooting downstream purification unit operations for customers, focusing on both novel and traditional modalities, across all purification technologies. He is also the High Temperature Short Time Subject Matter Expert for upstream viral risk mitigation. At University David obtained a BEng (Hons) in Chemical Engineering and an MSc in Advanced Chemical & Process Engineering. His early career was based in the nuclear and power generation sectors before moving into biopharmaceutical and life sciences.